melatonin has been researched along with Anxiety Disorders in 24 studies
Anxiety Disorders: Persistent and disabling ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PTSD is considered as a memory disorder within a Pavlovian fear conditioning and extinction framework." | 6.55 | The Melatonergic System in Anxiety Disorders and the Role of Melatonin in Conditional Fear. ( Huang, F; Li, CQ; Yang, Z, 2017) |
| "To assess urinary 6-sulphatoxymelatonin levels in a large consecutive series of patients with migraine and several comorbidities (chronic fatigue, fibromyalgia, insomnia, anxiety, and depression) as compared with controls." | 3.76 | Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. ( Cipolla-Neto, J; de Souza Vieira, DS; Lin, J; Masruha, MR; Minett, TS; Peres, MF; Vilanova, LC; Zukerman, E, 2010) |
| "PTSD is considered as a memory disorder within a Pavlovian fear conditioning and extinction framework." | 2.55 | The Melatonergic System in Anxiety Disorders and the Role of Melatonin in Conditional Fear. ( Huang, F; Li, CQ; Yang, Z, 2017) |
| "Delayed sleep phase disorder (DSPD) - a circadian rhythm sleep disorder - is most commonly seen in adolescents." | 2.49 | Circadian rhythm disorders among adolescents: assessment and treatment options. ( Armstrong, SM; Bartlett, DJ; Biggs, SN, 2013) |
| "Fluoxetine was ineffective in pinealectomized C3H or C57BL6 mice." | 1.32 | The pineal gland and anxiogenic-like action of fluoxetine in mice. ( Akhisaroglu, M; Dimitrijevic, N; Imbesi, M; Kurtuncu, M; Manev, H; Uz, T, 2004) |
| "L-5-Hydroxytryptophan (5HTP) was administered to 20 patients suffering from panic disorder and to 20 healthy controls." | 1.28 | Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. ( den Boer, JA; Westenberg, HG, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Leone, M | 1 |
| Kuja-Halkola, R | 1 |
| Lagerberg, T | 1 |
| Bjureberg, J | 1 |
| Butwicka, A | 1 |
| Chang, Z | 1 |
| Larsson, H | 1 |
| D'Onofrio, BM | 1 |
| Leval, A | 1 |
| Bergen, SE | 1 |
| Sundberg, I | 2 |
| Rasmusson, AJ | 1 |
| Ramklint, M | 2 |
| Just, D | 1 |
| Ekselius, L | 1 |
| Cunningham, JL | 2 |
| Bertani, DE | 1 |
| De Novellis, AMP | 1 |
| Farina, R | 1 |
| Latella, E | 1 |
| Meloni, M | 1 |
| Scala, C | 1 |
| Valeo, L | 1 |
| Galeazzi, GM | 1 |
| Ferrari, S | 1 |
| Carpenter, JS | 1 |
| Robillard, R | 1 |
| Hermens, DF | 2 |
| Naismith, SL | 2 |
| Gordon, C | 1 |
| Scott, EM | 1 |
| Hickie, IB | 2 |
| Söderquist, F | 1 |
| Widerström, R | 1 |
| Hellström, PM | 1 |
| De Berardis, D | 1 |
| Marini, S | 1 |
| Fornaro, M | 1 |
| Srinivasan, V | 2 |
| Iasevoli, F | 1 |
| Tomasetti, C | 1 |
| Valchera, A | 1 |
| Perna, G | 1 |
| Quera-Salva, MA | 1 |
| Martinotti, G | 1 |
| di Giannantonio, M | 1 |
| Bartlett, DJ | 1 |
| Biggs, SN | 1 |
| Armstrong, SM | 2 |
| Efron, D | 1 |
| Lycett, K | 1 |
| Sciberras, E | 1 |
| Marseglia, L | 1 |
| D'Angelo, G | 1 |
| Manti, S | 1 |
| Aversa, S | 1 |
| Arrigo, T | 1 |
| Reiter, RJ | 1 |
| Gitto, E | 1 |
| Huang, F | 1 |
| Yang, Z | 1 |
| Li, CQ | 1 |
| Kinrys, G | 1 |
| Coleman, E | 1 |
| Rothstein, E | 1 |
| Masruha, MR | 1 |
| Lin, J | 1 |
| de Souza Vieira, DS | 1 |
| Minett, TS | 1 |
| Cipolla-Neto, J | 1 |
| Zukerman, E | 1 |
| Vilanova, LC | 1 |
| Peres, MF | 1 |
| Brown, MA | 1 |
| Quan, SF | 1 |
| Eichling, PS | 1 |
| Paclt, I | 1 |
| Ptácek, R | 1 |
| Kuzelová, H | 1 |
| Cermáková, N | 1 |
| Trefilová, A | 1 |
| Kollárová, P | 1 |
| Cálková, T | 1 |
| Csemy, L | 1 |
| Cíhal, L | 1 |
| Ip, TK | 1 |
| Bolitho, S | 1 |
| Scott, E | 1 |
| Rogers, NL | 1 |
| Zakaria, R | 1 |
| Othman, Z | 1 |
| Lauterbach, EC | 1 |
| Acuña-Castroviejo, D | 1 |
| Heussler, H | 1 |
| Chan, P | 1 |
| Price, AM | 1 |
| Waters, K | 1 |
| Davey, MJ | 1 |
| Hiscock, H | 1 |
| Uz, T | 1 |
| Dimitrijevic, N | 1 |
| Akhisaroglu, M | 1 |
| Imbesi, M | 1 |
| Kurtuncu, M | 1 |
| Manev, H | 1 |
| Servant, D | 1 |
| Sandyk, R | 1 |
| Dann, LC | 1 |
| den Boer, JA | 1 |
| Westenberg, HG | 1 |
| McIntyre, IM | 2 |
| Judd, FK | 2 |
| Burrows, GD | 2 |
| Norman, TR | 2 |
| Golden, RN | 1 |
| Potter, WZ | 1 |
| Marriott, PF | 1 |
| Jefferys, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316] | Phase 2 | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| Follow-up Studies of PS and OSAHS in Chinese Children[NCT02447614] | 500 participants (Actual) | Observational [Patient Registry] | 2014-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 11 |
| Placebo | 10 |
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"
| Intervention | Mean Number of Openings (Mean) |
|---|---|
| Melatonin | 39 |
| Placebo | 60 |
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment
| Intervention | days (Mean) |
|---|---|
| Melatonin | 3.6 |
| Placebo | 4.9 |
Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks
| Intervention | minutes (Mean) |
|---|---|
| Melatonin | 15.2 |
| Placebo | 17.2 |
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
8 reviews available for melatonin and Anxiety Disorders
| Article | Year |
|---|---|
"Shedding Light on Light": A Review on the Effects on Mental Health of Exposure to Optical Radiation.
Topics: Anxiety; Anxiety Disorders; Circadian Rhythm; Humans; Melatonin; Mental Health | 2021 |
The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
Topics: Acetamides; Affect; Anxiety Disorders; Brain; Circadian Rhythm; Humans; Melatonin; Practice Patterns | 2013 |
Circadian rhythm disorders among adolescents: assessment and treatment options.
Topics: Adolescent; Anxiety Disorders; Australia; Comorbidity; Cross-Sectional Studies; Depressive Disorder; | 2013 |
Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics.
Topics: Analgesics; Anesthetics, General; Anti-Anxiety Agents; Anxiety Disorders; Brain Diseases; Child; Ele | 2015 |
The Melatonergic System in Anxiety Disorders and the Role of Melatonin in Conditional Fear.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Extinction, Psychological; Fear; Hippocamp | 2017 |
Natural remedies for anxiety disorders: potential use and clinical applications.
Topics: Anti-Anxiety Agents; Antioxidants; Anxiety Disorders; Humans; Hypericum; Inositol; Kava; Melatonin; | 2009 |
Agomelatine in depressive disorders: its novel mechanisms of action.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Disease Models, | 2012 |
[Biological rhythms and anxiety disorders].
Topics: Anxiety Disorders; Circadian Rhythm; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Melaton | 2006 |
1 trial available for melatonin and Anxiety Disorders
| Article | Year |
|---|---|
Use of sleep medication in children with ADHD.
Topics: Adolescent; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders; Attention Defici | 2014 |
15 other studies available for melatonin and Anxiety Disorders
| Article | Year |
|---|---|
Melatonin use and the risk of self-harm and unintentional injuries in youths with and without psychiatric disorders.
Topics: Accidental Injuries; Adolescent; Anxiety Disorders; Cohort Studies; Female; Humans; Male; Melatonin; | 2023 |
Daytime melatonin levels in saliva are associated with inflammatory markers and anxiety disorders.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Anxiety Disorders; CD5 Antigens; Chemokine | 2020 |
Sleep-wake profiles and circadian rhythms of core temperature and melatonin in young people with affective disorders.
Topics: Actigraphy; Adolescent; Adult; Anxiety Disorders; Body Temperature; Circadian Rhythm; Female; Humans | 2017 |
The Relationship Between Daytime Salivary Melatonin and Gastrointestinal Symptoms in Young Adults Seeking Psychiatric Care.
Topics: Adolescent; Adult; Anxiety Disorders; Circadian Rhythm; Comorbidity; Female; Humans; Irritable Bowel | 2019 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Circadian rhythm sleep disorder, free-running type in a sighted male with severe depression, anxiety, and agoraphobia.
Topics: Aged; Agoraphobia; Anxiety Disorders; Combined Modality Therapy; Depressive Disorder; Disease Progre | 2011 |
Circadian rhythms of saliva melatonin in ADHD, anxious and normal children.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Circadian Rhythm; Humans; M | 2011 |
Circadian profiles in young people during the early stages of affective disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Area Under Curve; Attention; Child; Circadian Rhythm; Depressi | 2012 |
Pharmacological and non-pharmacological management of sleep disturbance in children: an Australian Paediatric Research Network survey.
Topics: Adult; Aged; Anxiety Disorders; Australia; Behavior Therapy; Child; Clonidine; Comorbidity; Dose-Res | 2013 |
The pineal gland and anxiogenic-like action of fluoxetine in mice.
Topics: Animals; Anxiety Disorders; Arylamine N-Acetyltransferase; Denervation; Fluoxetine; Male; Melatonin; | 2004 |
Seasonal panic disorder: a possible variant of seasonal affective disorder.
Topics: Adult; Alprazolam; Anxiety Disorders; Circadian Rhythm; Combined Modality Therapy; Depressive Disord | 1992 |
Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder.
Topics: 5-Hydroxytryptophan; Anxiety Disorders; Arousal; beta-Endorphin; Blood Platelets; Fear; Female; Huma | 1990 |
Plasma concentrations of melatonin in panic disorder.
Topics: Adult; Alprazolam; Anxiety Disorders; Circadian Rhythm; Fear; Female; Humans; Male; Melatonin; Panic | 1990 |
Neurochemical and neuroendocrine dysregulation in affective disorders.
Topics: Acetylcholine; Anxiety Disorders; Arousal; Brain; Depressive Disorder; Hormones; Humans; Melatonin; | 1986 |
Melatonin in panic disorder.
Topics: Adult; Anxiety Disorders; Fear; Female; Humans; Male; Melatonin; Panic | 1986 |